Prof. Dr. med. Georg Schett

Lehrstuhl für Innere Medizin III

Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE (2021) D'Agostino MA, Schett G, Lopez-Rdz A, Senolt L, Fazekas K, Burgos-Vargas R, Maldonado-Cocco J, et al. Journal article Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52 (2021) Behrens F, Leage SL, Sapin C, El Baou C, De La Torre I, Meszaros G, Schett G, et al. Journal article Abatacept Reverses Subclinical Arthritis in Patients with High-risk to Develop Rheumatoid Arthritis -results from the Randomized, Placebo-controlled ARIAA Study in RA-at Risk Patients (2021) Rech J, Hueber A, Ostergaard M, Tascilar K, Hagen M, Mendez LV, Kleyer A, et al. Conference contribution Clusters of Psoriatic Arthritis Patients at Baseline Based on Different Ultrasound Detected Synovitis: Exploratory Analysis from a Phase III Study (2021) D'Agostino MA, Schett G, Gaillez C, Conaghan P, Naredo E, Carron P, Burgos-Vargas R, et al. Conference contribution Guselkumab (TREMFYA (R)) Maintains Resolution of Dactylitis and Enthesitis in Patients with Active Psoriatic Arthritis: Results Through 2 Years from a Phase 3 Study (2021) Rahman P, Mcinnes I, Deodhar A, Schett G, Mease P, Shawi M, Cua D, et al. Conference contribution Ultrasound Demonstrates Continued Improvement in Psoriatic Arthritis Synovitis and Enthesitis with Secukinumab: 52-week Results from a Phase III Study (2021) D'Agostino MA, Schett G, Gaillez C, Guerrero C, Hanova P, Cazenave T, Stoenoiu MS, et al. Conference contribution Bimekizumab in Patients with Psoriatic Arthritis: 3-Year Results for Overall and Tumor Necrosis Factor Inhibitor (TNFi)-Naive Populations from a Phase 2b Open-Label Extension Study (2021) Mease P, Deodhar A, Merola J, Mcinnes I, Assudani D, Bajracharya R, Coarse J, et al. Conference contribution Secukinumab Treatment Provides Sustained Resolution of Enthesitis at Individual Joints Through 52 Weeks in a Phase 3b, Double-Blind, Randomized, Active-Controlled Study (2021) Kaeley G, Schett G, Conaghan P, Mcgonagle D, Behrens F, Goupille P, Gaillez C, et al. Conference contribution Methotrexate Hampers Immunogenicity to BNT162b2 mRNA COVID-19 Vaccine in Immune-Mediated Inflammatory Disease (2021) Haberman R, Herati R, Simon D, Samanovic M, Tuen M, Blank R, Koralov S, et al. Conference contribution Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging (2021) Schmidkonz C, Rauber S, Atzinger A, Götz TI, Soare A, Cordes M, Prante O, et al. Journal article